News

31/01/2022 - General information

Research led by the Hospital del Mar Medical Research Institute selected in the first edition of the Cancer Innova project.

Glioblastoma and oral drugs for various types of cancer are among the targets of the projects for the first phase, selected from among more than a hundred proposals, due to their clinical and industrial relevance

The project "PARP2: a new therapeutic target in c-myc-driven tumours", headed up by Dr. José Yélamos, coordinator of the Poly (ADP-ribose) polymerase research group at the Hospital del Mar Medical Research Institute (IMIM) and the Immunology Service at Hospital del Mar, has been selected in the first edition of the Cancer Innova initiative, a consortium comprising the Kaertor Foundation and the Spanish Association Against Cancer in collaboration with the pharmaceutical companies Janssen and Lilly, which is supported by the Galician regional government. On this occasion, 110 proposals from eight countries were submitted, of which just five were selected based on their high clinical and industrial impact.

The research led by Dr. Yélamos seeks to obtain chemical compounds that inhibit the PARP2 protein, and which can be converted into oral drugs to combat a wide range of cancers. The IMIM team is led by doctors José Manuel Brea and Richard Roberts from the Kærtor Foundation.

Cancer Innova

The main objective of the Cancer Innova project is to speed up the delivery of oncology drugs to patients by identifying clinical needs not covered by current drugs in the field of oncology, in the shortest possible time and at the lowest possible cost. With an initial budget of close to five million euros, it is a pioneering innovation project open to Spain, but with a global scope that will generate economic and social well-being, helping new treatments to reach patients faster and creating a powerful international network against cancer.

More news